Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.